Genmab receives milestone payment for first Darzalex sale in Europe
pharmafile | May 31, 2016 | News story | Manufacturing and Production, Sales and Marketing | EU, FDA, Janssen, commercial, commercialised, daratumumab, darzalex, genman, multiple myeloma, sale, sales
Genmab (NASDAQ: GEN) has announced that the company is set to receive a milestone payment of $30 million from its collaborators, Janssen, after Darzalex (daratumumab) achieved its first commercial sale in Europe.
The European Commission granted a conditional approval for the multiple myeloma treatment in late May, based partly on strong late-stage trial data for the drug in combination with lenalidomide and dexamethasone. It was also approved by the US Food and Drug Administration (FDA) in late 2015.
It is indicated in the EU for use as monotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Jan van de Winkel, chief executive officer at Genmab, says: “We continue to be impressed by the rapid speed with which our collaboration partner, Janssen, has been able to develop and launch Darzalex in Europe.”
Janssen secured exclusive worldwide rights to develop, manufacture and commercialise the drug from Genmab. Currently, five Phase III trials are ongoing, while others are planned, to assess the use of Darzalex in other diseases where the CD38 molecule is expressed, such as smoldering myeloma, non-Hodgkin’s lymphoma and a solid tumour.
This milestone payment was included in previous financial guidance issued by Genmab
Sean Murray
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
